Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms
Companies Search For Novel Modalities, Enabling Technology
Executive Summary
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
You may also be interested in...
Remix Teams Up With Second Big Pharma With Roche Deal For RNA Technology
The news comes just under two years after Remix signed a partnership with J&J, and the biotech announced the same-day closing of a $60m financing to develop its lead product candidate.
Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Global R&D Heads Talk Superbugs, PROTACs And More
A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery